Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith Stewart

Showing results (151-160 of 208) with videos related to

Pageof 21
Sort By:
British Journal of Haematology|October 11, 2014
Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in -17p high risk diseaseKlaus M Kortüm, Christian Langer, Jorge Monge, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myelomaMartha Q Lacy, Suzanne R Hayman, Morie A Gertz, et al.
Blood|November 5, 2025
PIKfyve inhibition in myeloma disrupts autophagy and the lysosome, increasing MHC expression and cholesterol metabolismCecilia Bonolo De Campos, Ruijuan He, Tessa Josephine Pelino, et al.
Haematologica|December 22, 2022
Adjusted comparison of outcomes between patients from CARTITUDE-1 <i>versus</i> multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practiceMaria-Victoria Mateos, Katja Weisel, Thomas Martin, et al.
Blood|July 27, 2012
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myelomaDavid S Siegel, Thomas Martin, Michael Wang, et al.
Haematologica|October 5, 2019
Identification of PIKfyve kinase as a target in multiple myelomaCecilia Bonolo de Campos, Yuan Xiao Zhu, Nikolai Sepetov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2014
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantationAntonio Palumbo, S Vincent Rajkumar, Jesus F San Miguel, et al.
Blood Cancer Journal|December 18, 2019
Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myelomaJames Smadbeck, Jess F Peterson, Kathryn E Pearce, et al.
Blood|July 22, 2016
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myelomaHervé Avet-Loiseau, Rafael Fonseca, David Siegel, et al.
Blood|April 17, 2012
Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trialShaji K Kumar, Suzanne R Hayman, Francis K Buadi, et al.
Pageof 21

Showing results (151-160 of 208) with videos related to

Sort By:
Pageof 21
British Journal of Haematology|October 11, 2014
Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in -17p high risk diseaseKlaus M Kortüm, Christian Langer, Jorge Monge, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myelomaMartha Q Lacy, Suzanne R Hayman, Morie A Gertz, et al.
Blood|November 5, 2025
PIKfyve inhibition in myeloma disrupts autophagy and the lysosome, increasing MHC expression and cholesterol metabolismCecilia Bonolo De Campos, Ruijuan He, Tessa Josephine Pelino, et al.
Haematologica|December 22, 2022
Adjusted comparison of outcomes between patients from CARTITUDE-1 <i>versus</i> multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practiceMaria-Victoria Mateos, Katja Weisel, Thomas Martin, et al.
Blood|July 27, 2012
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myelomaDavid S Siegel, Thomas Martin, Michael Wang, et al.
Haematologica|October 5, 2019
Identification of PIKfyve kinase as a target in multiple myelomaCecilia Bonolo de Campos, Yuan Xiao Zhu, Nikolai Sepetov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2014
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantationAntonio Palumbo, S Vincent Rajkumar, Jesus F San Miguel, et al.
Blood Cancer Journal|December 18, 2019
Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myelomaJames Smadbeck, Jess F Peterson, Kathryn E Pearce, et al.
Blood|July 22, 2016
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myelomaHervé Avet-Loiseau, Rafael Fonseca, David Siegel, et al.
Blood|April 17, 2012
Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trialShaji K Kumar, Suzanne R Hayman, Francis K Buadi, et al.
Pageof 21